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We have previously demonstrated that certain platelet functions are modulated 
in  the  presence  of complement.  Thrombin-mediated  platelet aggregation  and 
release were significantly increased in the presence of the complement compo- 
nents C3, C5, C6, C7, C8, and C9. (1) Further,  when platelets were stimulated 
by thrombin  in  the presence of these complement  components,  C5b-9 dimers 
were visualized ultrastructurally  on the platelet membranes (2). Since the com- 
plement effect was inhibited by known inhibitors of platelet cyclo-oxygenase such 
as aspirin  and  indomethacin  it  was postulated  that  the  complement-mediated 
effect  was  mediated  via  the  arachidonic  acid  transformation  pathway  (2).  In 
further studies (3) it was found that arachidonate-mediated  release of serotonin 
and of Thromboxane B2 was significantly enhanced in the presence of the human 
complement components C5, C6, C7, C8, and C9. Dimers of the C5b-9 complex 
were similarly  visualized ultrastructurally  on the platelet surface subsequent to 
stimulation with arachidonate in the presence of C5-C9. 
It is the purpose of the present  study to demonstrate  an additional  role for 
complement in platelet physiologic processes. Human C3a was found to induce 
platelet aggregation and release of serotonin.  At concentrations below which it 
no longer induced these effects directly, the peptide showed significant synergism 
with ADP in  inducing  platelet aggregation  and  serotonin  release.  Removal of 
the C-terminus arginine  from C3a did not alter this effect on platelet function 
and  thus  it  was possible to localize the  platelet-stimulating  activity to the  C3a 
des-arg peptide. 
Materials and Methods 
Preparation of Gel-filtered Platelets.  The method used was a variation of several different 
methods (4-8) with  modifications  as follows: Blood (usually  100 mi) was drawn into a 
1  syringe that contained 1/6 volume acid citrate dextrose (ACD)  (9). In some experiments 
prostaglandin  El (PgE 0 (Sigma Chemical Co., St. Louis, MO) to a final concentration of 
100 nM (5) was also present in the syringe. The whole blood in ACD was centrifuged at 
90 g for  15 rain; the supernatant plus buffer layer were removed and recentrifuged at 
500 g for 6 min. The supernatant platelet-rich  plasma (PRP) was removed and was labeled 
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I Abbreviations used in  this paper:  ACD,  acid  citrate dextrose;  ADP,  adenosine diphosphate; 
ANOVA, analysis of variance; C4~,  fluid phase intermediate complex prepared from human 
C 1 esterase, C4 and oxidized C2; CPB, carboxypeptidase  B; EACT, 4b °~Y2a, erythrocyte intermediate 
complex prepared  from  sheep  cells sensitized with  rabbit anti-sheep cell antibody, and  human 
complement components C1, C4 and oxidized C2;  Hepes, N-2 hydroxyethylpiperazine-N-2-ethane 
sulfonic acid; LDH,  lactic dehydrogenase; MTHB,  modified Tyrode's buffer, pH 6.5  containing 
Hepes; PgEh prostaglandin El; PRP, platelet-rich plasma. 
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with  14C  serotonin  when  experiments  were  to  be  performed  to  measure  the  release 
reaction. The PRP either labeled with  14C serotonin, or unlabeled,  was centrifuged at 
1,200 g for 10 rain, and 2 ml modified Tyrodes's buffer, pH 6.5 containing 0.01  M N-2 
hydroxyethylpiperazine-N-2-ethane sulfonic acid (Hepes) (Sigma Chemical Co.) was added 
to the platelet button.  This buffer (MTHB) contained per liter:  8  g  sodium chloride, 
NaCI); 0.2 g potassium chloride (KCi);  0.057  g sodium phosphate (NaH2PO4.H20); 0.1 
g sodium bicarbonate (NaHCOs); 1.0 g dextrose, and 2 g bovine serum albumin. (Bovine 
serum albumin was obtained from Miles Laboratories, Inc., Elkhart,  IN). The platelet 
preparation was allowed to stand at 37°C for 15 min, then was applied to a 28 cmx  1.8 
cm column  of Sepharose  CL-2B (Pharmacia  Fine  Chemicals,  Div.  of Pharmacia  Inc., 
Piscataway, N  J) equilibrated with MTHB. The platelets emerged from the column as a 
sharp peak; the fractions containing the platelets were pooled, then the suspension was 
adjusted to the appropriate concentration (2.0-4.0 x  10~/#1) and the pH was adjusted to 
7.3 with 1 N sodium hydroxide (NaOH). 
Comparison of Gel  fltered Platelets with Washed Platelets 
A single donor was bled 200 ml into syringes containing ACD and PGE1 at the same 
concentration as those used when the platelets were to be gel-filtered alone. The whole 
blood was divided into two equal aliquots. Each aliquot was processed to a platelet button 
as described above. To the first aliquot was added  2 ml MTHB and the platelets were 
subjected to gel-filtration as described above. Platelets in the second aliquot were washed 
with the modified Ardlie Buffer system as previously described (1). The platelet concen- 
tration of both preparations was adjusted to 3.0 X 10~/~1. 
Purification of Complement Components.  C1 (10), Clg (11), C2 (12), C3 (13), C4 (14), C5 
(15),  C6, C7 (16), C8 (17), and C9 (18) were prepared from human serum by methods 
described earlier.  In addition, in some experiments, purified human complement com- 
ponents  C6,  C7,  C8,  and  C9  prepared  by Cordis  Laboratries,  Inc.,  Miami,  FL  were 
utilized. 
Preparation of Fluid Phase C3 Convertase (C4b°~Y2a).  40 ~tg C4 and  30 /zg °xyc2  (19) 
were incubated at 32°C for 10 min with 9 ~g Clg. 
Preparationof  Erythrocyte-bound  C3 Convertase (EACI, 4b, °XY2a).  The erythrocyte inter- 
mediate EAC 1,4b, °xY2a was prepared as described earlier. (20) 
Preparation of C3a.  2  mg of C3  were incubated for 30  min at  37°C  with either the 
fluid  phase  complex  prepared  as  above  or  with  2  x  101° packed  EACT, 
4b, °~Y2a. The third method used for the preparation of C3a was treatment of C3 with 
trypsin (21). C3 at 1 mg/ml was treated for 60 s at room temperature with 0.8% (wt/wt) 
trypsin (Worthington  Diagnostic Systems, Inc., Freehold,  N  J) (The trypsin was treated 
with L-(tosylamido 2-phenyl) ethyl chlormethyl ketone to inhibit contaminant chymotryptic 
activity). Soybean trypsin inhibitor (Calbiochem-Behring, La Jolla, CA) was added at twice 
the trypsin concentration.  In each case the preparation was immediately acidified to pH 
3.5, and subjected to molecular sieve chromotography on Sephadex G-100 (Pharmacia 
Fine Chemicals) equilibrated with acetate-buffered saline, pH 3.5 (21). 
Preparation of C3e 
C3 at 1 mg/ml was treated with 2% (wt/wt) trypsin for 2 h at 37°C. Soybean trypsin 
inhibitor was added at twice the trypsin concentration (22). 
Preparation of C5a 
C5 at 500/zg/ml was treated with 2% (wt/wt) trypsin for  12 min at 37°C.  Soybean 
trypsin inhibitor was added at twice the trypsin concentration (23). 
Platelet Aggregation 
Assays for platelet aggregation were performed in a Payton dual channel aggregometer 
equipped with a Riken Denshi recorder (Payton Associates, Inc., Buffalo, NY). Gel-filtered 
platelets were suspended at 2.0-4.0 x  105/~tl in MTHB. C3a and ADP (Sigma Chemical 
Co.)  were  added  singly  or  together  at  various  concentrations  to  0.4  ml  of platelets POLLEY  AND  NACHMAN  605 
containing 1.2 mM  CaCI2 and fibrinogen  at 900 #g/ml (Kabi Group, Inc.,  Greenwich, 
CT). The platelet  mixtures were stirred  for 5 rnin  while aggregation responses were 
recorded,  and when release  measurements were to  be made, the  samples were centrifuged 
and the supernatants were removed.  ~80%  of the gel-filtered  platclct  preparations 
showed suboptimal aggregation with I  0 #M ADP. Only one in five  preparations  aggre- 
gated optimally  with I  0 #M ADP alone.  Fur  the  purposes of  the  present  study,  gel-filtered 
platelets  that  reacted  minimally to  ADP alone  were used  to  study  the  effects  of  complement 
on aggregation. To quantitate  platelet  aggregation, the area under the curve of light 
transmission  was determined by tracing  the  curve 5 rain  after  the  addition  of  the  stimulus 
with  a planimeter No. 123A (Dietzgen Corp.,  Des Plaines,  IL)  three  times  and calculating 
the  average (24). 
In some experiments platelcts  were stimulated  with thrombin (kindly  supplied  by Dr. 
J. Fenton If, New York State  Department of  Health,  Albany, NY). 
Release  of~4C Serotonin.  Blood was drawn into  ACD as described  earlier,  but no PGE1 
was present  in the syringe.  Platelets  suspended in  plasma were labeled  with ~4C-serotonin 
by the method of  Valdorf-Hansen and Zucker (25).  The radiolabeled  platelets  were gel- 
filtered  in  the  usual  way. Various  reagents  were added to  0.4 ml of  the  gel-filtered  platelet 
preparation  and aggregation recorded for 5 rain.  Then the tube was rapidly  centrifuged 
and the supernatant was transferred to another tube, t4C was counted in both the 
supernate  and the  cell  button in  a  Packard liquid  Scintillation  counter (Packard Instrument 
Co.,  Inc.,  Downers Grove, IL)  and the percentage of  release  was calculated. 
Removal of Ca ÷+ and Mg+÷  from Platelet-suspending Buffer (MTHB).  Trace amounts of 
Ca  ++ and Mg  ++ contained in MTHB were removed by addition of Chelex  100 (Bio-Rad, 
Rockville Centre, NY) followed by filtration through a Chelex  100 column as previously 
described (8). 
Release of Lactic Dehydrogenase (LDH).  LDH was determined by the method of Wrob- 
iewski and LaDue (26).  1U was expressed as decrease in OD at 340 ~m of 0.001/min per 
ml. A control sample giving 100% lysis was obtained by the addition of 0.1% Triton X- 
100. 
Removal of C-Terminus Amino Acid Arginine from C3a.  22 nmol of C3a were incubated 
at pH 7.6 for 30 rain with various concentrations of carboxypeptidase B(2.5 nmol,  12.5 
nmol, 25 nmol) (CPB). As a control, bradykinin at the same molar concentration as C3a 
was treated with similar amounts of CPB. 
The effect of CPB on C3a was analyzed on a flat plate high voltage apparatus (Savant 
Instruments, Inc. Hicksville, NY) at 1 kV for 60-70 rain using 20 cm X 20 cm cellulose 
coated thin-layer chromatography plates (EM Laboratories, Elmsford, NY) and a pyridine 
acetic acid buffer ofpH 6.4 (27). For analytical purposes 15 nmol of C3a or 15 nmol of 
C3a treated with CPB were applied. As a control  15 nmol of bradykinin or  15 nmol of 
bradykinin treated with CPB were also applied.  Arginine was used as a  marker. After 
drying the plates were stained with a solution of 0.5% ninhydrin in acetone. 
C3a Anaphylatoxin Activity.  Anaphylatoxin activity was measured on segments of iso- 
lated guinea pig ileum as previously described (23). 
Statistical Analysis 
Statistical  analyses  were  performed  on  a  Hewlett-Packard  9815A  computer  using 
prepared programs of the Hewlett-Packard statistics library (09815-15001) for one- and 
two-way analysis of variance (ANOVA).  Although  the  data  are  displayed  in  tables as 
percentages of control, analyses of variance were performed using the nontransformed 
data. (24) 
Immuno-ultrastructural Studies 
Preparation of F(ab')~ fragments of anti-C3a and anti-C3c.  Monospecific antiserum  to 
human C3a was prepared in rabbits by injection of the purified protein into the popliteal 
lymph nodes followed a month later by intramuscular injections of the same protein (28). 
The antiserum was extensively tested immuno-chemically for specificity and was found to 
be monospecific for C3a.  The y-globulin fraction was prepared from the antiserum as 606  C3a,  C3a  DES-ARG  ACTIVATE  HUMAN  PLATELETS 
described earlier  (29).  The  ~,-globulin fraction  of monospecific  antibody to  C3c was 
purchased from Dako Corp., Santa Barbara, CA. The purified ~,-globulin fraction of each 
antibody was digested with pepsin and the F(ab')~ fragments were isolated by molecular 
sieve chromatography on Sephadex G-150 as described earlier (29). 
The F(ab')~ fraction of each antibody was conjugated with gold by the method of Frens 
(30) as modified by Handley et al. (31). 
Reaction of Gel-filtered Platelets with C3a 
To each of eight  1-ml aliquots  of gel-filtered  platelets  at 300,000/#1 containing  1.2 
mM CaCI2 and fibrinogen (900 #g/ml) was added  1.2 #g C3a.  Duplicate  samples were 
allowed to incubate at 37°C with stirring for periods of 30 s, 60 s, or 5 min, or at 0°C for 
5 min. At the end of the incubation period the samples were immediately  cooled to 0°C. 
The platelets in each sample were washed three times with ice-cold sterile saline and then 
were resuspended to 1 ml. To one aliquot of platelets  from each incubation period was 
added 10 #g of gold-conjugated F(ab')2 fragment of anti-C3a,  and to the second aliquot 
was added  10 #g of gold-conjugated F(ab')~ fragment of anti-C3c.  The mixtures were 
allowed to stand at 2-4°C for 16 h, then the platelets were washed three times with saline. 
Preparation of Platelet Membranes  for Electron Microscopy 
The washed platelets  were further washed once in a  1:15 dilution  of saline and then 
alternatively  frozen at -70°C and thawed three times. The resultant platelet membranes 
were washed three times in the diluted saline and then were applied unstained to copper 
grids coated with  collodion and  carbon.  The  grids were viewed under  a  Philips  301 
Electron  Microscope (Philips Electronic  Instruments, Inc., Mahwah, N  J) at 80 kV. 
Results 
Effect of C3a on Aggregation of Gel-fltered Platelets.  C3, activated by fluid phase 
i~4b2a, EAC1,  4b2a or by trypsin was fractioned by molecular sieve chromatog- 
raphy on Sephadex G-100 into two major protein peaks (a typical protein profile 
is  shown  in  Fig.  1).  C3a  was  localized  to  fractions  #78-92  as  measured  by 
anaphylatoxin activity using isolated guinea pig ileum segments and immunologic 
reactivity with a monospecific antibody to C3a. A known C3a marker of tool wt 
9,000 emerged in the same fractions.  Each fraction of the column was tested in 
addition for its ability to aggregate gel-filtered platelets. The fractions containing 
C3a  caused  marked  aggregation  of  the  gel-filtered  platelets.  (Fig.  1).  This 
response was not inhibited by prior exposure of the platelets to aspirin (100 #M). 
Addition of C3 alone; C3b; C3e; C5 alone; C5a; C3, C5, C6, C7, C8, and C9 or 
C5, C6, C7, C8, and C9 did not induce the aggregation of gel-filtered platelets. 
C3a-mediated aggregation  of gel-filtered platelets was found to be Ca  ++ de- 
pendent.  Optimal aggregation  was obtained at Ca  ++ concentrations of 0.6-2.0 
mM. When Mg  ÷+ was added at similar concentrations,  the platelets aggregated 
less well than they did in the presence of Ca  ++ . 
The method of platelet preparation significantly influenced the responsiveness 
of platelets to the complement peptide.  Platelets isolated from one donor were 
split in  two separate aliquots,  one was processed as above by gel filtration;  the 
other aliquot  was processed by the  multiple  washing  procedure  (1).  The  gel- 
filtered platelets responded  to C3a while the  washed platelets were refractory 
(Fig. 2). 
C3a alone at low concentrations  (2  ×  10  -12 M) failed to aggregate  platelets. 
ADP alone  at  10  #M  also failed  to induce  platelet activation.  When  platelets 
were stimulated with both agents together, significant aggregation occurred (Fig. POLLEY  AND  NACHMAN  607 
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FIGURE  l.  Isolation of C3a and C3b by molecular sieve chromatography on Sephadex C- 
100 and correlation of the distribution of C3a with platelet-stimulating  activity. 50 mg of C3 
was applied  to the column after treatment with 0.8% trypsin  (wt/wt) for 60 s at 20°C. The 
column was equilibrated  with 0.15 M acetate-buffered sodium chloride, pH 3.5. The solid bar 
indicates the only fractions from the column that mediated platelet aggregation. Inset shows 
platelet aggregometer tracings obtained when platelets were stimulated  with C3a and C3b. In 
the experiment shown, to 0.4 ml gel-filtered platelets at 300,000/t~l  was added at time 0 either 
100 ng C3a or 38 #g C3b in the presence of 1.2 mM CaCI~  and fibrinogen at 500 #g/ml. 
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FIGURE 2.  Platelet aggregometer tracings obtained when platelets from the same donor that 
had been separated from plasma proteins by either gel-filtration or by the =washing"  procedure 
(See Materials and Methods) were stimulated  with C3a at 2 X 10  -11 M. 
3).  To  demonstrate  that C3a and ADP synergistically induced platelet  aggrega- 
tion,  gel-filtered  platelets  were  incubated  with  ADP  alone,  C3a  alone,  and 
combinations  of ADP  and  C3a at  various concentrations.  The  data  in Table  I 
show that when ADP and C3a were combined the resultant platelet aggregation 
was  greater  than  the  sum  of the  aggregations  generated  by each  agent  alone; 
this  type  of  result  defines  synergism.  The  interaction  (synergy)  was  highly 





FmURE  3.  Platetet aggregometer tracings obtained when platelets were stimulated with C3a 
(2 x  I0  -l~ M) or ADP (10 gM) singly or combined at the same concentrations. 
TABLE  I 
Synergy between C3a and ADP in Platelet Aggregation 
ADP (#M) 
C3a (M) 
0  10  -~  2 ×  10  -~  5 ×  10  -1~ 
% Platelet aggregation* 
0  0  0  5+0.7  13+  1.4 
10  7 -  0.7  56 -  2  83 +  4  100 
*  Gel-filtered platelets were  stimulated with C3a  alone,  ADP alone,  or 
combinations of C3a and ADP at the concentrations indicated. Aggre- 
gation was allowed to proceed for 5 min, then the area under the curve 
was measured planimetrically. The results are expressed as a percentage 
of the value obtained when platelets were stimulated with ADP (10 uM) 
and C3a (5 x  10  -l~ M) together. 
Statistical analysis was  performed  by  two-way  analysis of variance to 
assess  the  significance  of the  effects  of  each  agent  alone  and  their 
combination, with the following results: Pe~, PADP, Psr,,r~ all <0.0001. 
Platelet-stimulating Activity of C3a des-arg 
C3a was treated with CPB using conditions previously shown to remove the 
C-terminal arginine (27). Treatment of C3a by CPB resulted in the liberation of 
free arginine as  demonstrated by high  voltage electrophoresis.  The resultant 
C3a des arg had no anaphylatoxin activity but retained full platelet-stimulating 
activity (Table II). When combined, C3a des-arg and ADP exhibited a synergism 
on platelet aggregation (P <  0.0001) that was identical to the synergism exhibited 
by C3a and ADP. 
Effect of C3a and C3a des-arg on Platelet Serotonin Release 
C3a and C3a des-arg at identical concentrations induced similar degrees of 
serotonin release from stimulated platelets (Fig. 4A). There was no difference in 
the release-inducing effect of C3a  or  C3a  des-arg  when compared singly or 
together with ADP. (Fig. 4B). To demonstrate that C3a des-arg together with 
ADP synergistically induced platelet serotonin release, gel-filtered platelets were 
incubated with ADP alone, C3a des-arg alone, and combinations of ADP and 
C3a des-arg at various concentrations. The data in Table III show that when 
ADP and C3a des-arg were combined, the resulting serotonin release was greater POLLEY  AND  NACHMAN 
TABLE  II 
Anaphylatoxin and Platelet-stimulating Activity of C3a and C3a des- 
arg 
609 
Anaphylatoxin ac-  Platelet aggregation 
tivity 
%  %* 
C3a  100  100 
C3a des-arg  0  98 +  4 
* Gel-filtered platelets were stimulated with C3a or C3a des-arg at the 
same concentration (5 x  10  -H M). Aggregation was allowed to proceed 
for 5 min, then the area under the curve was measured planimetrically 
and the data were expressed as a percentage of the value obtained when 
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FtC,  URE  4.  (A) Release of platelet serotonin mediated by C3a and C3a des-arg at 10  -11 M. (B) 
Release of platelet serotonin mediated by ADP (10 uM); C3a or C3a des arg (2  x  10  -l~ M) 
singly; or ADP together with C3a or C3a des arg at the same concentrations. 
TABLE  III 
Synerg  3 between C3a des-arg and ADP in Platelet Secretion 
ADP (#M) 
C3a des-arg (M) 
0  2  X  10 -12  6  X  10 -~ 
% HC serotonin release* 
0  0  12-+5  33-+2 
1  6-+2  57-+10  67-+4 
10  13-_.4  56-+3  69+3 
* Gel-filtered platelets were stimulated with C3a des-arg alone, ADP alone, 
or combinations of C3a des-arg and ADP at the concentrations indicated. 
Aggregation was allowed to proceed for 5 min, then the percentage of 
release of 14C serotonin was determined as described in Materials and 
Methods. 
Statistical analysis was  performed  by  two-way  analysis of variance to 
assess  the  effects  of each  agent  alone  and  in  combination,  with  the 
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than the sum of the release generated by each agent alone. The synergy was 
highly  significant  (P  <  0.001  by  two-way  ANOVA).  Identical  results  were 
obtained with C3a and ADP. No release of LDH was measurable at any concen- 
tration of C3a or C3a des-arg tested alone or in combination with ADP. 
Lack of Synergism between C3a and Thrombin in Platelet Aggregation 
Gel-filtered platelets  were incubated  with  C3a  alone,  thrombin alone,  and 
combinations of C3a and thrombin at various concentrations. As indicated in 
Table IV, when thrombin and C3a were combined, the resultant platelet aggre- 
gation was not significantly greater than the sum of the aggregation generated 
by each agent alone. This finding indicated lack of synergy between C3a and 
thrombin. 
Immuno-ultrastructural Localization of C3a on the Platelet Membrane 
Subsequent to C3a Stimulation 
As  demonstrated  in  Fig.  5A  C3a  was  present  on  the  platelet  membrane 
subsequent to C3a stimulation at all incubation periods tested as evidenced by 
visualization  of the  ultrastructural  probe,  gold,  conjugated  to  monospecific 
antibody to C3a. No such gold probe was seen on the platelet surface before C3a 
stimulation. (Fig.  5B).  No native C3 was present on the platelet surface either 
before or after C3a stimulation as demonstrated by the absence of gold on the 
platelet membrane when the ultrastructural probe was conjugated to anti-C3c 
(Fig. 5 C and D). 
Discussion 
The present studies demonstrate a new biologic activity that is associated with 
the human complement system. C3a,  the small fragment (Mr 9000)  liberated 
from C3 by its specific activating enzyme C3 convertase (or by trypsin), induced 
TABLE  IV 
Lack of Synergy between C3a and Thrombin in Platelet Aggregation 
Thrombin (U) 
C3a 
0  1.5 x  10 -~ M 
% platelet aggregation* 
0  0  48 +_ 12.7 
0.002  4 +  3.1  57  _+ 12.8 
0.004  10 ±  2.3  64 4- 2 
0.005  33 ±  12  73 ± 6 
0.01  74 ± 8.1  100 
* Gel-filtered platelets were stimulated with C3a alone, thrombin alone, 
or combinations of C3a and thrombin at the concentrations indicated. 
Aggregation was allowed to proceed for 5 min, then the area under the 
curve  was  measured planimetrically. The  results are  expressed as  a 
percentage of the value  obtained when the platelets were stimulated 
with thrombin (0.01  U) and C3a (1.5 x  10  -H M) together. 
Statistical analysis was performed by  two-way analysis of variance  to 
assess the  significance of the  effects of each  agent  alone  and  their 
combination. The results indicated lack of significant synergism between 
C3a and thrombin (P,~rsy >0.45). POLLEY  AND  NACHMAN  611 
FIGURE 5.  Immunoelectron microscopy of C3a on the platelet  surface.  (A and B) Platelets 
treated with  gold-conjugated anti-C3a.  (A) C3a-treated platelets.  (B) Untreated platelets.  (C 
and D) Platelets treated with gold-conjugated anti-C3c. (C) C3a-treated platelets. (D) Untreated 
platelets. All preparations were unstained.  The gold probe was only seen in A, which indicated 
the  presence  of C3a  on  the  platelet  membrane only subsequent  to C3a stimulation.  The 
absence  of native  C3 on the platelet  membrane either before or after C3a stimulation  was 
indicated  by the absence of the gold marker when anti-C3c was employed.  X 264,000. 
aggregation and seroto~in  release  from gel-filtered  human  platelets.  At concen- 
trations of 10  -1° M  to 5  x  10  -is M, C3a induced aggregation when added alone 
to the preparation  of gel-filtered  platelets.  However, at lower concentrations (2 
x  10  -i~  M)  C3a  did  not  aggregate  platelets  directly,  but  exhibited  highly 612  C3a,  C3a  DES-ARG  ACTIVATE  HUMAN  PLATELETS 
significant synergism (P <  0.0001) with ADP in mediating platelet aggregation 
and serotonin release. Previous studies by others (32, 33) have shown that human 
and guinea pig C3a activate guinea pig platelets but not human platelets. In these 
previous studies the platelets were subjected to extensive washing procedures to 
free the cells from plasma proteins. In our studies the platelets were separated 
from the plasma proteins by a more gentle gel filtration procedure. Our studies 
(Fig.  2)  clearly  demonstrate  that  the  method  used  to  prepare  the  platelets 
significantly influenced the responsiveness of the platelets to the complement 
peptide. It is not clear at present why the C3a-mediated activation of platelets 
should be significantly affected by the technique of platelet isolation. However, 
our data suggest the possibility that human platelets may have a  receptor for 
C3a.  If this turns out to be the case, it is possible that the washing procedure 
induces sufficient trauma to the platelet so that it affects the receptor sterically 
or otherwise, in such a way that it precludes its eventual acceptance of C3a in an 
active form. 
The  synergy  exhibited  between  C3a  and  ADP,  but  not  between  C3a  and 
thrombin, is of interest.  Most,  if not all of platelet agonists act synergistically 
(34), and platelet activation in vivo probably involves a combination of agonists 
acting in concert. These particular relationships may have potential relevance in 
the micro environment of vascular damage, where sub-optimal amounts of ADP 
released  from  activated  platelets  can  interact  with  adjacent  platelet  surfaces 
preconditioned  by  contact  with  C3a  generated  in  the  vicinity of damage  by 
complement-activating mechanisms, including thrombin generation at the plate- 
let surface (1). The synergistic interaction of ADP and C3a in these circumstances 
may be important factors in modulating platelet membrane responses to physio- 
logically activating stimuli. 
The significance of the lack of synergy between C3a and thrombin remains to 
be  fully  clarified,  however  the  observation  is  compatible  with  our  previous 
suggestion that complement may function in these circumstances to regulate the 
fine  tuning  of the  membrane  to  subtle  rather  than  maximal  stimulation  (3). 
Huang and Detwiler (34) have suggested that different combinations of platelet 
agonists will elicit variable degrees of synergy depending on the mode of action 
and  the  concentrations  of  the  individual  agonists.  The  specific  mechanisms 
involved in  C3a-induced  as  well  as  thrombin-induced trans  membrane  signal 
generation remain to be clarified. 
As demonstrated in the present study, C3a activated platelets at concentrations 
higher than 5 ×  10 -12 M and at 2 x  10 -1~ M exhibited highly significant synergism 
with ADP in mediating platelet aggregation and serotonin release.  These con- 
centrations involve relatively small numbers of molecules per platelet (10,000 
and 4,000 respectively), and suggest the possibility of a C3a receptor on human 
platelets. This premise is strengthened by the demonstration ultrastructurally of 
the presence of C3a on the platelet membrane surface subsequent to stimulation 
with C3a (Fig. 5). Studies are currently underway to isolate and characterize a 
specific C3a receptor, on the human platelet surface. 
It is of considerable biologic interest that the C-terminus arginine of C3a was 
not required for its platelet-stimulating activity. C3a and C3a des-arg were equally 
reactive in mediating platelet aggregation and release of serotonin. Further, both POLLEY  AND  NACHMAN  613 
exhibited synergism with ADP of equal significance in  both aggregation and 
release. In vivo the C3a anaphylatoxin inactivator cleaves the C-terminus arginine 
from C3a, thereby ablating its anaphylatoxin activity (27). Previously no biologic 
activity  was  known  to  be  associated  with  C3a  des-arg.  Recently (35)  it  was 
reported that  this peptide inhibits in  vitro  natural  killer cell  activity.  In  the 
present study, a  second biologic activity has been described for C3a des-arg, 
namely, that it is a peptide with potent platelet-stimulating activity. The biologic 
importance of circulating C3a des-arg in various clinical states following comple- 
ment activation remains to be determined. 
We have previously reported that human complement plays an important role 
in  platelet  physiologic processes.  Thrombin-mediated platelet  activation  was 
significantly enhanced  in  the  presence  of C3-C9  (1)  and  transformation  of 
arachidonate into thromboxane B~ via the cyclooxygenase pathway was much 
increased in the presence of C5-C9 (3).  The present study describes a  further 
role  for  complement in  platelet  physiology. The  significance of the  present 
observation is related to the fact that C3, the parent molecule from which C3a 
is derived is a key complement component. Activation of the complement system 
by the classical pathway, alternative pathway, or by the thrombin-platelet pathway 
(1) all lead to cleavage of the C3 molecule and thereby liberation of C3a. Since 
C3 is present in plasma at the highest concentration of any of the complement 
components (,~ 1.3  mg/ml) activation of the complement system by any of the 
known pathways can lead to the production of amounts of C3a (C3a des-arg) 
that may play an important role in regulating platelet function in hemostatic as 
well as thrombotic events. 
Summary 
C3a liberated from C3 by treatment with C3 convertase (or by trypsin) induced 
aggregation of gel-filtered human platelets and stimulated serotonin release. At 
concentrations of 10 -~° M to 8 x  10 -~2 M, C3a induced aggregation when added 
alone to platelets. However, at lower concentrations (2 x  I 0 -1~ M) C3a did not 
aggregate platelets directly but exhibited highly significant synergism (two-way 
analysis of variance P <  0.0001) with ADP in mediating platelet aggregation and 
release of serotonin. Removal of the C-terminus arginine from C3a abolished 
anaphylotoxin activity but did not affect the platelet-stimulating activity of the 
peptide. C3a and C3a des-arg were equally reactive in mediating platelet aggre- 
gation and release of serotonin. Further C3a and C3a des-arg exhibited synergism 
with ADP of equal significance in both aggregation and the release reaction. 
The concentrations of C3a required for the platelet-stimulating activity involve 
relatively small number of molecules per platelet (4,000-10,000  for the syner- 
gistic reaction with ADP). These data suggest the possibility of a C3a (C3a des- 
arg) receptor on human platelets. This premise is strengthened by the demon- 
stration ultrastructurally of C3a on the platelet membrane subsequent to C3a 
stimulation. 
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